Chondrosarcoma surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
'''Indications''' | '''Indications''' | ||
*Mesenchymal chondrosarcoma | *Mesenchymal chondrosarcoma | ||
===Limb-salvage through Pelvic Resection with or without Reconstruction=== | |||
'''Indications''' | |||
*Dedifferentiated chondrosarcoma involving the pelvis<ref name="pmid15523011">{{cite journal| author=Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH et al.| title=Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. | journal=J Bone Joint Surg Am | year= 2004 | volume= 86-A | issue= 11 | pages= 2412-8 | pmid=15523011 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15523011 }} </ref> | |||
===Limb-sacrifice with Hindquarter Amputation=== | |||
'''Indications''' | |||
*Dedifferentiated chondrosarcoma involving the pelvis<ref name="pmid15523011">{{cite journal| author=Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH et al.| title=Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. | journal=J Bone Joint Surg Am | year= 2004 | volume= 86-A | issue= 11 | pages= 2412-8 | pmid=15523011 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15523011 }} </ref> | |||
===Recurrence Rate=== | ===Recurrence Rate=== | ||
Revision as of 00:41, 24 January 2019
|
Chondrosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chondrosarcoma surgery On the Web |
|
American Roentgen Ray Society Images of Chondrosarcoma surgery |
|
Risk calculators and risk factors for Chondrosarcoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]
Overview
Surgery is the mainstay of treatment for chondrosarcoma. Adjunctive chemotherapy and radiation may be required. Recurrence rate depends on the grade of chondrosarcoma.
Surgery
Intra-Lesional Curettage
Indications
- Grade 1 chondrosarcoma involving the extremities
Wide Surgical Excision
Indications
- Grade 2 or 3 chondrosarcoma anywhere in the body
- Grade 1 chondrosarcoma in pelvis
Wide Surgical Excision Combined with Multi-Agent Chemotherapy
Indications
- Mesenchymal chondrosarcoma
Limb-salvage through Pelvic Resection with or without Reconstruction
Indications
- Dedifferentiated chondrosarcoma involving the pelvis[6]
Limb-sacrifice with Hindquarter Amputation
Indications
- Dedifferentiated chondrosarcoma involving the pelvis[6]
Recurrence Rate
Grade 1 chondrosarcoma
- It is rare after wide resection with negative margins.
- 5-15% is the recurrence rate after curettage with adjuvant treatment.
Grade 2 chondrosarcoma
- The recurrence rate varies depending on resection margins.
Grade 3 chondrosarcoma
- The local recurrence rate is 25% and >30% chances of metastasis.
References
- ↑ Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.
- ↑ Czerniak, Bogdan (2016). Dorfman and Czerniak's bone tumors. Philadelphia, PA: Elsevier/Saunders. ISBN 9780323023962.
- ↑ Lex JR, Evans S, Stevenson JD, Parry M, Jeys LM, Grimer RJ (2018). "Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment". Clin Sarcoma Res. 8: 23. doi:10.1186/s13569-018-0110-1. PMC 6293503. PMID 30559960.
- ↑ Ozaki T, Lindner N, Hillmann A, Rödl R, Blasius S, Winkelmann W (1996). "Influence of intralesional surgery on treatment outcome of chondrosarcoma". Cancer. 77 (7): 1292–7. doi:10.1002/(SICI)1097-0142(19960401)77:7<1292::AID-CNCR10>3.0.CO;2-X. PMID 8608505.
- ↑ Marco RA, Gitelis S, Brebach GT, Healey JH (2000). "Cartilage tumors: evaluation and treatment". J Am Acad Orthop Surg. 8 (5): 292–304. PMID 11029557.
- ↑ 6.0 6.1 Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH; et al. (2004). "Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes". J Bone Joint Surg Am. 86-A (11): 2412–8. PMID 15523011.